



29 Emmons Drive Suite C-10 Princeton, NJ 08540

T (609) 538-8200 • F (609) 452-6467

Overview

Soligenix, Inc. (Soligenix) (OTCBB: SNGX) is a latestage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for selected bioterrorism agents. Soligenix's lead product, orBec[®] (oral beclamethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation (HCT).

Investment Highlights

- Potential for exponential growth with the achievement of a single milestone: a positive confirmatory Phase 3 clinical trial of orBec[®] in acute GI GVHD.
- Confirmatory Phase 3 clinical trial for orBec[®] in the treatment of acute GI GVHD, agreed to by the FDA through its Special Protocol Assessment (SPA) procedure, as well as by the European Medicines Agency (EMA) through its protocol assistance procedure. The primary endpoint of the study will be to replicate the statistically significant secondary endpoint from the previous Phase 3 study where a p-value of 0.005 was achieved. This study is enrolling patients and is targeted to complete in the first half of 2011.
- Clean capital structure with no debt or preferred stock outstanding. FDA and EMA regulatory clarity provide path to approval for orBec[®] pending positive clinical results.
- An NIH grant-supported Phase 2 clinical trial with orBec[®] enrolling for the prevention of acute GVHD has completed enrollment with results expect in the second half of 2010.
- orBec[®] for the treatment and prevention of GVHD addresses up to a \$400 million global market, where there is currently an unmet medical need and no approved therapies. Soligenix has entered into a 35% royalty-generating North American partnership deal with Sigma-Tau Pharmaceuticals.
- Oral BDP, the active ingredient of orBec[®], has the potential to treat other inflammatory diseases of the GI tract, such as radiation enteritis (SGX201), radiation injury (SGX202) and Crohn's disease (SGX203), representing markets in excess of \$500 million annually worldwide.
- A Phase 1/2 study evaluating the safety of SGX201 for the prevention of acute radiation enteritis, supported by an approximate \$500,000 NIH SBIR grant award, has been initiated and is targeted to be complete in the first half of 2011.
- Soligenix is developing a novel Lipid Polymer Micelle (LPM[™]) delivery system for enhancing the oral bioavailability of water-soluble drugs, such as leuprolide, that are not ordinarily absorbed or are degraded in the GI tract.
- Soligenix is the world leader in ricin toxin vaccine research, and a Phase 1 study with its vaccine, RiVax[™], is actively enrolling. The biodefense vaccine programs are supported by NIH grant funding, with approximately \$25 million to date.
- Soligenix currently has four active clinical trials across its spectrum of biotherapeutics and biodefense.
- In September 2009, the company announced receipt of a \$9.4 million grant from the NIH to fund development over the next five years of formulation and manufacturing processes for vaccines that are stable at elevated temperatures.

www.soligenix.com

Stock Snapshot

OTC BB: SNGX

Recent Stock Price: \$0.27

Market Cap: \$50 million as of
May 31, 2010

Executive Team

Christopher J. Schaber, PhD
President & CEO

Evan Myriantopoulos
Chief Financial Officer

Brian L. Hamilton, MD, PhD
Chief Medical Officer

Robert N. Brey, PhD
Chief Scientific Officer

Christopher Schmittker, CPA
VP, Administration & Controller

Board of Directors

Christopher J. Schaber, PhD
Chairman, President & CEO

Evan Myriantopoulos
Director & Chief Financial Officer

Cyrille Buhrman
Director

Gregg Lapointe, CPA, MBA
Director

Robert J. Rubin, MD
Director

General Contact

Soligenix, Inc.
29 Emmons Drive
Suite C-10
Princeton, NJ 08540

Telephone: (609) 538-8200
Fax: (609) 452-6467
info@soligenix.com

